Deccan Health Care Ltd

Deccan Healthcar has experienced fluctuating financial performance, with net sales increasing from INR 33.17 crore in March 2022 to INR 75.06 crore in March 2025, but operating profit and cash flow remain negative, indicating ongoing operational challenges. Total assets and liabilities have both risen to INR 124.93 crore by March 2025.

Deccan Healthcar will announce its results on 14 November 2025.

As of 07-Nov, Deccan Health Care Ltd's stock price is at 16.35, down 3.54% over the last four days and 8.91% for the week, with year-to-date and one-year returns of -44.10% and -41.61%, respectively. The stock's weak performance is attributed to poor long-term fundamentals and declining investor confidence, contrasting with the Sensex's minor decline of 0.86% over the same period.

As of 28-Oct, Deccan Health Care Ltd's stock price is at 16.32, having increased by 4.48% recently, with a total return of 10.42% over the last three days. Despite this short-term gain, the stock has a year-to-date decline of 44.21%, indicating significant long-term challenges.

As of 13-Oct, Deccan Health Care Ltd's stock price is Rs. 14.98, down 8.77% and at a 52-week low. The stock has declined 23.69% over the past week and 48.79% year-to-date, significantly underperforming the market and its sector.

As of 08-Oct, Deccan Health Care Ltd's stock price is Rs 17.03, down 5.65% and has underperformed its sector by 4.99%. The stock has shown high volatility and a year-to-date return of -41.78%, reflecting weak financial fundamentals and negative market sentiment.

As of October 6, 2025, Deccan Healthcare's valuation has improved to attractive, indicating it is undervalued with a PE ratio of 42.12, an EV to EBITDA of 13.43, and a low EV to Book Value of 0.41, especially when compared to peers like Sun Pharma and Cipla.

As of 06-Oct, Deccan Health Care Ltd's stock price is declining at 18.52, down 3.54%, and has fallen 5.65% over the last two days. The stock is underperforming significantly compared to the broader market, with a year-to-date decrease of 36.68% and negative returns across multiple periods.

As of September 25, 2025, Deccan Healthcar's valuation has shifted from attractive to fair, with a high PE ratio of 45.26 and underperformance of -31.97% year-to-date compared to the Sensex, indicating it is not a compelling investment opportunity despite not being overvalued.

As of 25-Sep, Deccan Health Care Ltd's stock price is at 19.90, reflecting a recent increase but a significant decline of -28.72% over the past year. Despite a short-term rally, the stock faces challenges with weak fundamentals and decreased investor participation.

As of September 24, 2025, Deccan Healthcare's valuation has improved to attractive, indicating it may be undervalued with a PE ratio of 44.49, a low price-to-book value of 0.43, and a favorable EV to EBITDA ratio of 14.23 compared to peers, despite a year-to-date stock decline of 33.13%.

As of September 22, 2025, Deccan Healthcar is considered fairly valued with a PE ratio of 45.46, lagging behind peers like Cipla and Sun Pharma, and has underperformed the Sensex with a return of -27.69% over the past year.

Deccan Healthcar has shown steady growth in net sales and total assets from March 2022 to March 2025, but profitability has declined, with operating profit and profit after tax decreasing significantly. The company faces challenges in generating positive cash flow from operations.

As of September 17, 2025, Deccan Healthcar is considered undervalued and has an attractive valuation grade compared to its peers in the healthcare services industry, despite a year-to-date return of -32.24%, with key ratios indicating potential for growth.